Dr. Reddy's Laboratories falls Friday, underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares slid 1.27% to 1,354.20 Indian rupees Friday, on what proved to be an all-around ...
Dr. Reddy's Laboratories outperforms market on strong trading day
Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...
Dr Reddys Share Price Highlights: Dr. Reddy's Laboratories ends the day at Rs 1370.75
Join us on the Dr Reddys Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay ...
Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Can Dr Reddy’s shrug off Revlimid’s patent expiry?
DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories ends the day at Rs 1371.6
Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...
Geode Capital Management LLC Buys 6,920 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)
Geode Capital Management LLC increased its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 109.3% ...
Dr. Reddy’s Sells Non-Strategic Louisiana Subsidiary
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
ndtvprofit2d
Dr. Reddy's Gets 'Buy' Upgrade From Nuvama On Plans To Mitigate Key Patent Loss
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
Dr. Reddy’s Laboratories (NYSE:RDY) Stock Passes Above 200-Day Moving Average – Should You Sell?
Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.49 and traded ...
Dr Reddy's surges 4% on Nuvama upgrade to 'buy', bullishness on efforts to mitigate Revlimid expiry impact
Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.
Dr. Reddy’s Laboratories’ Credit Rating Reaffirmed by ICRA
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.